A Virtual Screen to Identify of Hit stage Inhibitors of all four serotypes of Dengue Polymerase (360G-Wellcome-109660_Z_15_Z)
Dengue virus is a mosquito-borne infection that causes a severe flu-like illness and, in a subset of cases, the potentially lethal complications of Dengue Haemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS). The World Health Organization estimates 50 million cases of Dengue infection annually worldwide. This project is a unique structure-based approach to develop novel Dengue inhibitors that target a key stage in the virus lifecycle, the prevention of the viral replication and are active against all four serotypes.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 94306 |
| Applicant Surname | Cockerill |
| Approval Committee | Pathfinders Assessment Group |
| Award Date | 2015-08-25T00:00:00+00:00 |
| Financial Year | 2014/15 |
| Grant Programme: Title | Pathfinder Award |
| Internal ID | 109660/Z/15/Z |
| Lead Applicant | Dr Stuart Cockerill |
| Partnership Value | 94306 |
| Planned Dates: End Date | 2017-09-07T00:00:00+00:00 |
| Planned Dates: Start Date | 2016-04-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | North East |